Tryptamine guanosine carbamate

Cat. No.: HY-138885 CAS No.: 1414808-96-0 Molecular Formula: $C_{21}H_{23}N_{7}O_{6}$ Molecular Weight: 469.45 Target: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Others

Product Data Sheet

BIOLOGICAL ACTIVITY

Pathway:

Description	Tryptamine guanosine carbamate (TpGc) is a selective HINT1 (histidine triad nucleotide-binding protein 1) inhibitor (K_i =34 μ M, K_d =3.65 μ M). Tryptamine guanosine carbamate significantly enhances morphine antinociception while preventing the development of tolerance ^[1] .
In Vivo	Pretreatment with 20 nmol Tryptamine guanosine carbamate enhances morphine antinociception in 129 HINT1 ^{+/+} mice and is devoid of effect in HINT1 ^{-/-} mice. The administration of 7 and 20 nmol of Tryptamine guanosine carbamate 20min before the morphine priming dose significantly reduces the development of acute antinociceptive tolerance in HINT1 ^{+/+} mice but not in HINT1 ^{-/-} animals ^[1] . Tryptamine guanosine carbamate reduces the recruitment of NMDAR activity promoted by morphine. In mice suffering from chronic constriction injury concurrent with increased NMDAR activity, a single intracerebroventricular administration of Tryptamine guanosine carbamate (20 nmol) attenuates NMDAR function and alleviated mechanical allodynia for several days ^[1] .
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Garzón J, et al. HINT1 protein: a new therapeutic target to enhance opioid antinociception and block mechanical allodynia. Neuropharmacology. 2015;89:412-423.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA